PRKDC
DNA-dependent protein kinase catalytic subunit
As of the edition of 20 October 2026, PRKDC (DNA-dependent protein kinase catalytic subunit, UniProt P78527) has 6 drugs tested at it and 7 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P78527
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 52
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Digestive system; Heart and blood vessels; Hormones; Lungs and airways
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 2 |
| Status not established | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nedisertib | Stopped | Phase 2 | none listed |
| CC-115 | Status not established | Phase 2 | none listed |
| BY101298 | Stopped | Phase 2 | none listed |
| Bosmolisib | Active | Phase 2 | none listed |
| XRD-0394 | Status not established | Phase 1 | none listed |
| AZD-7648 | Status not established | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Merck KGaA | Route A |
| Chengdu Baiyu Pharmaceutical | Route A |
| Merck Healthcare KGaA | Route A |
The other 4 companies at PRKDC
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at PRKDC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.